semaglutide bilirubin Can Cause Liver Damage? Safety Evidence Explained Glucagon-like peptide-1 receptor agonist, semaglutide
Description
The shift in gut motility, combined with changes in bile acid absorption and fluid balance in the intestines, can lead to diarrhea, particularly during dose increases
Fluid accumulation may play a role in rapid weight gain and dyspnea in morbid obesity
Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities
Frontline Gastroenterology
The primary endpoint was achievement of HbA 1c of less than 7% (53 mmol/mol) at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52
Your provider monitors your progress and adjusts your treatment as needed
